Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.56 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6193746 | 0.80 | HCRTR1 (0.55) | HCRTR1HCRTR2KDM4ETSHRNPC1 | |
| SCHEMBL6233177 | 0.78 | ACACB (0.53) | PARP1KDM4ETSHRNPC1RAB9A | |
| SCHEMBL13141982 | 0.75 | HCRTR1 (0.52) | HCRTR1HCRTR2KDM4ETSHRRAB9A | |
| SCHEMBL20339488 | 0.72 | HTR3E (0.63) | HCRTR1HCRTR2PARP1KDM4ENPC1 | |
| SCHEMBL4147974 | 0.72 | POLB (0.51) | HCRTR1HCRTR2KDM4ENPC1RAB9A | |
| SCHEMBL6186684 | 0.72 | SMN1; SMN2 (0.60) | HCRTR1HCRTR2KDM4ETSHRLMNA | |
| SCHEMBL1672568 | 0.72 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL13118532 | 0.71 | CHRM2 (0.48) | HCRTR1HCRTR2KDM4EMAPK1TSHR | |
| SCHEMBL6480598 | 0.71 | PARP1 (0.48) | PARP1KDM4EMAPK1TSHRRCE1 | |
| SCHEMBL14758421 | 0.70 | ALDH1A1 (0.57) | HCRTR1HCRTR2KDM4EMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2005538968-A | — | — | 2005-12-22 | — | — | JP | claimed |
| EP-1517898-A1 | ARYLCARBONYLPIPERAZINES AND HETEROARYLCARBONYLPIPERAZINES AND THE USE THEREOF FOR TREATING BENIGN AND MALIGNANT TUMOUR DISEASES | Zentaris GmbH (DE) | 2005-03-30 | — | — | EP | claimed |
| WO-2004002965-A1 | ARYLCARBONYLPIPERAZINES AND HETEROARYLCARBONYLPIPERAZINES AND THE USE THEREOF FOR TREATING BENIGN AND MALIGNANT TUMOUR DISEASES | ZENTARIS GMBH (DE) | 2004-01-08 | — | — | WO | claimed |
| EP-1517898-A1 | ARYLCARBONYLPIPERAZINES AND HETEROARYLCARBONYLPIPERAZINES AND THE USE THEREOF FOR TREATING BENIGN AND MALIGNANT TUMOUR DISEASES | Zentaris GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| US-20040097734-A1 | Aryl- and heteroarylcarbonylpiperazines and their use for the treatment of benign and malignant oncoses | ZENTARIS GMBH (DE) | 2004-05-20 | — | — | US | disclosed |
| WO-2004002965-A1 | ARYLCARBONYLPIPERAZINES AND HETEROARYLCARBONYLPIPERAZINES AND THE USE THEREOF FOR TREATING BENIGN AND MALIGNANT TUMOUR DISEASES | ZENTARIS GMBH (DE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097734-A1 | Aryl- and heteroarylcarbonylpiperazines and their use for the treatment of benign and malignant oncoses | VHL, MYC, HCCS | HCRTR1 308/4885HCRTR2 439/4885PARP1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.